View ValuationTrident Texofab 将来の成長Future 基準チェック /06現在、 Trident Texofabの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Retail Distributors 収益成長12.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹0.54 (vs ₹2.44 in FY 2025)Full year 2026 results: EPS: ₹0.54 (down from ₹2.44 in FY 2025). Revenue: ₹1.20b (down 1.8% from FY 2025). Net income: ₹7.05m (down 72% from FY 2025). Profit margin: 0.6% (down from 2.1% in FY 2025). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.お知らせ • May 22Trident Texofab Limited to Report Q4, 2026 Results on May 28, 2026Trident Texofab Limited announced that they will report Q4, 2026 results on May 28, 2026Valuation Update With 7 Day Price Move • May 06Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹44.87, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 24x in the Retail Distributors industry in India. Total loss to shareholders of 30% over the past three years.Valuation Update With 7 Day Price Move • Apr 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹55.17, the stock trades at a trailing P/E ratio of 25.7x. Average trailing P/E is 22x in the Retail Distributors industry in India. Total loss to shareholders of 20% over the past three years.Valuation Update With 7 Day Price Move • Mar 16Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to ₹44.97, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 21x in the Retail Distributors industry in India. Total loss to shareholders of 27% over the past three years.New Risk • Mar 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹917.0m (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.9x net interest cover). Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (₹917.0m market cap, or US$9.98m). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Large one-off items impacting financial results.Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹0.39 (vs ₹0.30 in 3Q 2025)Third quarter 2026 results: EPS: ₹0.39 (up from ₹0.30 in 3Q 2025). Revenue: ₹262.2m (down 17% from 3Q 2025). Net income: ₹5.70m (up 90% from 3Q 2025). Profit margin: 2.2% (up from 0.9% in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.9x net interest cover). High level of non-cash earnings (24% accrual ratio). Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Market cap is less than US$100m (₹1.97b market cap, or US$21.7m).Valuation Update With 7 Day Price Move • Feb 09Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to ₹153, the stock trades at a trailing P/E ratio of 77.9x. Average trailing P/E is 25x in the Retail Distributors industry in India. Total returns to shareholders of 79% over the past three years.お知らせ • Feb 06Trident Texofab Limited to Report Q3, 2026 Results on Feb 12, 2026Trident Texofab Limited announced that they will report Q3, 2026 results at 3:30 PM, Indian Standard Time on Feb 12, 2026お知らせ • Nov 05Trident Texofab Limited to Report Q2, 2026 Results on Nov 13, 2025Trident Texofab Limited announced that they will report Q2, 2026 results on Nov 13, 2025お知らせ • Aug 28Trident Texofab Limited, Annual General Meeting, Sep 25, 2025Trident Texofab Limited, Annual General Meeting, Sep 25, 2025, at 16:00 Indian Standard Time.Reported Earnings • Aug 15First quarter 2026 earnings released: EPS: ₹0.72 (vs ₹0.69 in 1Q 2025)First quarter 2026 results: EPS: ₹0.72 (up from ₹0.69 in 1Q 2025). Revenue: ₹285.2m (up 11% from 1Q 2025). Net income: ₹10.2m (up 46% from 1Q 2025). Profit margin: 3.6% (up from 2.7% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Aug 07Trident Texofab Limited to Report Q1, 2026 Results on Aug 12, 2025Trident Texofab Limited announced that they will report Q1, 2026 results on Aug 12, 2025Reported Earnings • May 30Full year 2025 earnings released: EPS: ₹2.38 (vs ₹1.07 in FY 2024)Full year 2025 results: EPS: ₹2.38 (up from ₹1.07 in FY 2024). Revenue: ₹1.25b (up 26% from FY 2024). Net income: ₹25.1m (up 132% from FY 2024). Profit margin: 2.0% (up from 1.1% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 21Trident Texofab Limited to Report Q4, 2025 Results on May 29, 2025Trident Texofab Limited announced that they will report Q4, 2025 results on May 29, 2025New Risk • Apr 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 35% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.8x net interest cover). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₹2.34b market cap, or US$27.3m).Reported Earnings • Feb 04Third quarter 2025 earnings released: EPS: ₹0.30 (vs ₹0.55 in 3Q 2024)Third quarter 2025 results: EPS: ₹0.30 (down from ₹0.55 in 3Q 2024). Revenue: ₹314.3m (up 37% from 3Q 2024). Net income: ₹3.00m (down 46% from 3Q 2024). Profit margin: 1.0% (down from 2.4% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Jan 31Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹157, the stock trades at a trailing P/E ratio of 73.2x. Average trailing P/E is 32x in the Retail Distributors industry in India. Total returns to shareholders of 196% over the past three years.お知らせ • Jan 29Trident Texofab Limited to Report Q3, 2025 Results on Feb 03, 2025Trident Texofab Limited announced that they will report Q3, 2025 results on Feb 03, 2025Valuation Update With 7 Day Price Move • Oct 24Investor sentiment improves as stock rises 40%After last week's 40% share price gain to ₹105, the stock trades at a trailing P/E ratio of 49x. Average trailing P/E is 47x in the Retail Distributors industry in India. Total returns to shareholders of 141% over the past three years.Recent Insider Transactions • Oct 18MD & Executive Chairman recently sold ₹54m worth of stockOn the 16th of October, Hardik Desai sold around 1m shares on-market at roughly ₹54.13 per share. This transaction amounted to 32% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Hardik has been a net seller over the last 12 months, reducing personal holdings by ₹59m.Reported Earnings • Oct 14Second quarter 2025 earnings released: EPS: ₹1.00 (vs ₹0.75 in 2Q 2024)Second quarter 2025 results: EPS: ₹1.00 (up from ₹0.75 in 2Q 2024). Revenue: ₹292.1m (up 26% from 2Q 2024). Net income: ₹10.0m (up 33% from 2Q 2024). Profit margin: 3.4% (up from 3.2% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.お知らせ • Oct 08Trident Texofab Limited to Report Q2, 2025 Results on Oct 12, 2024Trident Texofab Limited announced that they will report Q2, 2025 results at 3:30 PM, Indian Standard Time on Oct 12, 2024お知らせ • Aug 22Trident Texofab Limited, Annual General Meeting, Sep 27, 2024Trident Texofab Limited, Annual General Meeting, Sep 27, 2024, at 16:00 Indian Standard Time.Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹44.56, the stock trades at a trailing P/E ratio of 23.6x. Average trailing P/E is 49x in the Retail Distributors industry in India. Total returns to shareholders of 23% over the past three years.Reported Earnings • Jul 20First quarter 2025 earnings released: EPS: ₹0.69 (vs ₹0.13 loss in 1Q 2024)First quarter 2025 results: EPS: ₹0.69 (up from ₹0.13 loss in 1Q 2024). Revenue: ₹265.8m (up 15% from 1Q 2024). Net income: ₹6.96m (up ₹8.24m from 1Q 2024). Profit margin: 2.6% (up from net loss in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 13Trident Texofab Limited to Report Q1, 2025 Results on Jul 17, 2024Trident Texofab Limited announced that they will report Q1, 2025 results on Jul 17, 2024Recent Insider Transactions • Jul 02MD & Executive Chairman recently sold ₹4.5m worth of stockOn the 27th of June, Hardik Desai sold around 94k shares on-market at roughly ₹48.33 per share. This transaction amounted to 2.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Hardik's only on-market trade for the last 12 months.Valuation Update With 7 Day Price Move • Jul 01Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹40.16, the stock trades at a trailing P/E ratio of 37.5x. Average trailing P/E is 50x in the Retail Distributors industry in India. Total returns to shareholders of 4.9% over the past three years.Reported Earnings • Feb 15Third quarter 2024 earnings released: EPS: ₹0.55 (vs ₹1.14 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.55 (down from ₹1.14 in 3Q 2023). Revenue: ₹231.2m (down 5.8% from 3Q 2023). Net income: ₹5.58m (down 52% from 3Q 2023). Profit margin: 2.4% (down from 4.7% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 07Trident Texofab Limited to Report Q3, 2024 Results on Feb 14, 2024Trident Texofab Limited announced that they will report Q3, 2024 results on Feb 14, 2024お知らせ • Oct 28Trident Texofab Limited to Report Q2, 2024 Results on Nov 06, 2023Trident Texofab Limited announced that they will report Q2, 2024 results on Nov 06, 2023お知らせ • Oct 12Trident Texofab Limited Announces Resignation of Deepak Prakashchandra Gandhi from the BoardTrident Texofab Limited informed that Mr. Deepak Prakashchandra Gandhi has vide his resignation letter dated October 11, 2023, resigned from the Board of the Company with effect from the closure of business hours on 11th October, 2023.Valuation Update With 7 Day Price Move • Sep 11Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹73.75, the stock trades at a trailing P/E ratio of 40.1x. Average trailing P/E is 39x in the Retail Distributors industry in India. Total returns to shareholders of 157% over the past three years.Reported Earnings • Aug 12First quarter 2024 earnings released: ₹0.13 loss per share (vs ₹0.23 profit in 1Q 2023)First quarter 2024 results: ₹0.13 loss per share (down from ₹0.23 profit in 1Q 2023). Revenue: ₹231.8m (flat on 1Q 2023). Net loss: ₹1.29m (down 154% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.お知らせ • Aug 11+ 1 more updateTrident Texofab Limited, Annual General Meeting, Sep 29, 2023Trident Texofab Limited, Annual General Meeting, Sep 29, 2023, at 17:00 Indian Standard Time.お知らせ • Jul 29Trident Texofab Limited to Report Q1, 2024 Results on Aug 10, 2023Trident Texofab Limited announced that they will report Q1, 2024 results on Aug 10, 2023お知らせ • Jul 16Trident Texofab Limited Announces Resignation of Vrusti Bhumik Patel as Independent DirectorTrident Texofab Limited announced that Mrs. Vrusti Bhumik Patel has vide her resignation letter dated 15 July 2023, resigned from the board of the company with effect from the closure of business hours on 15 July 2023.Board Change • Jul 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. Executive & Non-Independent Director Manish Halwawala was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jun 04Trident Texofab Limited Announces Resignation of Rushi Hemantkumar Jagani as DirectorTrident Texofab Limited announced that Mr. Rushi Hemantkumar Jagani has vide his resignation letter dated June 2, 2023, resigned from the Board Of the Company with effect from the closure of business hours on 02nd June, 2023. Due to personal reasons and pre-occupation elsewhere and there is no other material reason for resignation.Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹63.55, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 27x in the Retail Distributors industry in India. Total returns to shareholders of 47% over the past three years.Valuation Update With 7 Day Price Move • Feb 07Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹66.05, the stock trades at a trailing P/E ratio of 23.5x. Average trailing P/E is 33x in the Retail Distributors industry in India. Total returns to shareholders of 80% over the past three years.Reported Earnings • Jan 18Third quarter 2023 earnings released: EPS: ₹1.14 (vs ₹0.15 in 3Q 2022)Third quarter 2023 results: EPS: ₹1.14 (up from ₹0.15 in 3Q 2022). Revenue: ₹252.9m (up 6.0% from 3Q 2022). Net income: ₹11.5m (up ₹10.0m from 3Q 2022). Profit margin: 4.5% (up from 0.6% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 10Trident Texofab Limited to Report Q3, 2023 Results on Jan 16, 2023Trident Texofab Limited announced that they will report Q3, 2023 results at 3:30 PM, Indian Standard Time on Jan 16, 2023お知らせ • Jan 03Trident Texofab Limited Appoints Rahul Jariwala as Company Secretary and Compliance OfficerTrident Texofab Limited has approved the appointment of Mr. Rahul Jariwala as a Company Secretary and Compliance officer of the company with effective from 02 January, 2023.Valuation Update With 7 Day Price Move • Dec 07Investor sentiment improved over the past weekAfter last week's 25% share price gain to ₹102, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 43x in the Retail Distributors industry in India. Total returns to shareholders of 170% over the past three years.お知らせ • Oct 12Trident Texofab Limited Approves Resignation of Sanju Patel as Company Secretary and Compliance OfficerTrident Texofab Limited at its meeting held on October 11, 2022, the Board of Directors approved resignation of Ms. Sanju Patel from the post of Company Secretary and Compliance Officer, effective closure of business hours on October 11, 2022 due to her personal reasons.Reported Earnings • Oct 12Second quarter 2023 earnings released: EPS: ₹0.77 (vs ₹0.02 in 2Q 2022)Second quarter 2023 results: EPS: ₹0.77 (up from ₹0.02 in 2Q 2022). Net income: ₹7.77m (up ₹7.62m from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Oct 05Trident Texofab Limited to Report Q2, 2023 Results on Oct 11, 2022Trident Texofab Limited announced that they will report Q2, 2023 results on Oct 11, 2022お知らせ • Aug 23Trident Texofab Limited, Annual General Meeting, Sep 26, 2022Trident Texofab Limited, Annual General Meeting, Sep 26, 2022, at 11:00 Indian Standard Time. Location: 5th Floor, Office Building Nr. Sahara Darwaja Surat IndiaRecent Insider Transactions • Aug 09MD & Executive Chairman recently sold ₹3.6m worth of stockOn the 4th of August, Hardik Desai sold around 32k shares on-market at roughly ₹114 per share. In the last 3 months, they made an even bigger sale worth ₹5.9m. Hardik has been a seller over the last 12 months, reducing personal holdings by ₹12m.お知らせ • Jul 09Trident Texofab Limited Announces Resignation of Board MembersTrident Texofab Limited announced the resignation of Ms. Ami Ashwinbhai Desai and inducting Mrs. Natasha Karbhari, Independent Director as new Member of the Audit Committee, Nomination & Remuneration Committee and member of Relationship Committee, with immediate effect.お知らせ • Jul 07Trident Texofab Limited to Report Q1, 2023 Results on Jul 12, 2022Trident Texofab Limited announced that they will report Q1, 2023 results at 3:30 PM, Indian Standard Time on Jul 12, 2022お知らせ • Jul 02Trident Texofab Limited Announces Resignation of Ami Ashwinbhai Desai as Independent DirectorTrident Texofab Limited informed that Ms. Ami Ashwinbhai Desai has tendered her resignation due to her personal reasons and other professional commitments as an Independent Director from the Board of Directors of the Company vide her letter dated July 1, 2022 effective the closure of business hours on 09th July, 2022.Recent Insider Transactions • Jun 07MD & Executive Chairman recently sold ₹707k worth of stockOn the 3rd of June, Hardik Desai sold around 7k shares on-market at roughly ₹101 per share. In the last 3 months, they made an even bigger sale worth ₹5.9m. Hardik has been a seller over the last 12 months, reducing personal holdings by ₹8.2m.Recent Insider Transactions • May 28MD & Executive Chairman recently sold ₹5.9m worth of stockOn the 25th of May, Hardik Desai sold around 60k shares on-market at roughly ₹98.89 per share. This was the largest sale by an insider in the last 3 months. Hardik has been a seller over the last 12 months, reducing personal holdings by ₹7.5m.Recent Insider Transactions • Apr 30MD & Executive Chairman recently sold ₹5.6m worth of stockOn the 27th of April, Hardik Desai sold around 55k shares on-market at roughly ₹103 per share. This was the largest sale by an insider in the last 3 months. This was Hardik's only on-market trade for the last 12 months.Reported Earnings • Apr 27Full year 2022 earnings released: EPS: ₹0.98 (vs ₹0.35 in FY 2021)Full year 2022 results: EPS: ₹0.98 (up from ₹0.35 in FY 2021). Revenue: ₹850.3m (up 70% from FY 2021). Net income: ₹9.83m (up 178% from FY 2021). Profit margin: 1.2% (up from 0.7% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 34% per year, which means it is well ahead of earnings.お知らせ • Apr 16Trident Texofab Limited to Report Q4, 2022 Results on Apr 21, 2022Trident Texofab Limited announced that they will report Q4, 2022 results on Apr 21, 2022Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹63.35, the stock trades at a trailing P/E ratio of 72.5x. Average trailing P/E is 49x in the Retail Distributors industry in India. Total returns to shareholders of 58% over the past three years.Reported Earnings • Oct 22Second quarter 2022 earnings released: EPS ₹0.02 (vs ₹0.14 in 2Q 2021)The company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹212.9m (up 36% from 2Q 2021). Net income: ₹157.0k (down 89% from 2Q 2021). Profit margin: 0.1% (down from 0.9% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improved over the past weekAfter last week's 28% share price gain to ₹50.55, the stock trades at a trailing P/E ratio of 48.6x. Average trailing P/E is 53x in the Retail Distributors industry in India. Total returns to shareholders of 23% over the past three years.Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹40.00, the stock trades at a trailing P/E ratio of 38.7x. Average trailing P/E is 52x in the Retail Distributors industry in India. Total loss to shareholders of 5.3% over the past three years.Reported Earnings • Jul 02Full year 2021 earnings released: EPS ₹0.35 (vs ₹0.90 in FY 2020)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹499.3m (down 45% from FY 2020). Net income: ₹3.53m (down 59% from FY 2020). Profit margin: 0.7% (down from 0.9% in FY 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.Executive Departure • Apr 21Non-Executive Non-Independent Director has left the companyOn the 15th of April, Maniya Desai's tenure as Non-Executive Non-Independent Director ended after 3.9 years in the role. As of December 2020, Maniya personally held only 98.20k shares (₹3.0m worth at the time). A total of 2 executives have left over the last 12 months.Executive Departure • Apr 02Company Secretary & Compliance Officer has left the companyOn the 31st of March, Mehul Amareliya's tenure as Company Secretary & Compliance Officer ended after 3.1 years in the role. We don't have any record of a personal shareholding under Mehul's name. Mehul is the only executive to leave the company over the last 12 months.Reported Earnings • Feb 12Third quarter 2021 earnings released: EPS ₹0.08 (vs ₹0.24 in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹140.0m (down 30% from 3Q 2020). Net income: ₹790.0k (down 66% from 3Q 2020). Profit margin: 0.6% (down from 1.2% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.お知らせ • Feb 05Trident Texofab Limited to Report Q3, 2021 Results on Feb 11, 2021Trident Texofab Limited announced that they will report Q3, 2021 results on Feb 11, 2021Is New 90 Day High Low • Feb 02New 90-day low: ₹24.25The company is down 7.0% from its price of ₹26.00 on 04 November 2020. The Indian market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is up 30% over the same period.Is New 90 Day High Low • Dec 12New 90-day high: ₹33.10The company is up 20% from its price of ₹27.50 on 11 September 2020. The Indian market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Retail Distributors industry, which is up 14% over the same period.Is New 90 Day High Low • Nov 25New 90-day high: ₹30.00The company is up 2.0% from its price of ₹29.30 on 27 August 2020. The Indian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is up 7.0% over the same period.Reported Earnings • Nov 13Second quarter 2021 earnings released: EPS ₹0.14The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: ₹158.2m (down 29% from 2Q 2020). Net income: ₹1.45m (up 5.5% from 2Q 2020). Profit margin: 0.9% (up from 0.6% in 2Q 2020). The increase in margin was driven by lower expenses.お知らせ • Nov 06Trident Texofab Limited to Report Q2, 2021 Results on Nov 11, 2020Trident Texofab Limited announced that they will report Q2, 2021 results on Nov 11, 2020Is New 90 Day High Low • Oct 26New 90-day low: ₹26.15The company is down 14% from its price of ₹30.31 on 27 July 2020. The Indian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is up 8.0% over the same period.Is New 90 Day High Low • Oct 08New 90-day low: ₹26.40The company is down 11% from its price of ₹29.58 on 10 July 2020. The Indian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is up 13% over the same period.お知らせ • Aug 18Trident Texofab Limited to Report Q1, 2021 Results on Aug 20, 2020Trident Texofab Limited announced that they will report Q1, 2021 results on Aug 20, 2020お知らせ • Jun 20Trident Texofab Limited to Report Q4, 2020 Results on Jun 25, 2020Trident Texofab Limited announced that they will report Q4, 2020 results on Jun 25, 2020 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Trident Texofab は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BSE:540726 - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20261,1807-102-96N/A12/31/20251,22732N/AN/AN/A9/30/20251,28630-139-139N/A6/30/20251,24428N/AN/AN/A3/31/20251,22125-137-137N/A12/31/20241,14019N/AN/AN/A9/30/20241,05322-10N/A6/30/20241,02119N/AN/AN/A3/31/2024995112727N/A12/31/202393612N/AN/AN/A9/30/2023951182527N/A6/30/202396119N/AN/AN/A3/31/2023964225659N/A12/31/202296628N/AN/AN/A9/30/202295918-1520N/A6/30/202292811N/AN/AN/A3/31/202284310-2814N/A12/31/20217899N/AN/AN/A9/30/20216909-4558N/A6/30/202163610N/AN/AN/A3/31/20214994-8020N/A12/31/20205321N/AN/AN/A9/30/20205922-20-11N/A6/30/20206602N/AN/AN/A3/31/20209109-46-29N/A12/31/20191,0039N/AN/AN/A9/30/201997110N/A-77N/A6/30/201992412N/AN/AN/A3/31/201986913N/A-28N/A12/31/201880012N/AN/AN/A9/30/201888111N/AN/AN/A6/30/20188848N/AN/AN/A3/31/20188558N/A-24N/A3/31/20177593N/A1N/A3/31/20166601N/A7N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 540726の予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 540726の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 540726の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 540726の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 540726の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 540726の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YRetail 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 09:15終値2026/06/10 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Trident Texofab Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹0.54 (vs ₹2.44 in FY 2025)Full year 2026 results: EPS: ₹0.54 (down from ₹2.44 in FY 2025). Revenue: ₹1.20b (down 1.8% from FY 2025). Net income: ₹7.05m (down 72% from FY 2025). Profit margin: 0.6% (down from 2.1% in FY 2025). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
お知らせ • May 22Trident Texofab Limited to Report Q4, 2026 Results on May 28, 2026Trident Texofab Limited announced that they will report Q4, 2026 results on May 28, 2026
Valuation Update With 7 Day Price Move • May 06Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹44.87, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 24x in the Retail Distributors industry in India. Total loss to shareholders of 30% over the past three years.
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹55.17, the stock trades at a trailing P/E ratio of 25.7x. Average trailing P/E is 22x in the Retail Distributors industry in India. Total loss to shareholders of 20% over the past three years.
Valuation Update With 7 Day Price Move • Mar 16Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to ₹44.97, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 21x in the Retail Distributors industry in India. Total loss to shareholders of 27% over the past three years.
New Risk • Mar 08New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹917.0m (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.9x net interest cover). Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Market cap is less than US$10m (₹917.0m market cap, or US$9.98m). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Large one-off items impacting financial results.
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹0.39 (vs ₹0.30 in 3Q 2025)Third quarter 2026 results: EPS: ₹0.39 (up from ₹0.30 in 3Q 2025). Revenue: ₹262.2m (down 17% from 3Q 2025). Net income: ₹5.70m (up 90% from 3Q 2025). Profit margin: 2.2% (up from 0.9% in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.9x net interest cover). High level of non-cash earnings (24% accrual ratio). Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Market cap is less than US$100m (₹1.97b market cap, or US$21.7m).
Valuation Update With 7 Day Price Move • Feb 09Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to ₹153, the stock trades at a trailing P/E ratio of 77.9x. Average trailing P/E is 25x in the Retail Distributors industry in India. Total returns to shareholders of 79% over the past three years.
お知らせ • Feb 06Trident Texofab Limited to Report Q3, 2026 Results on Feb 12, 2026Trident Texofab Limited announced that they will report Q3, 2026 results at 3:30 PM, Indian Standard Time on Feb 12, 2026
お知らせ • Nov 05Trident Texofab Limited to Report Q2, 2026 Results on Nov 13, 2025Trident Texofab Limited announced that they will report Q2, 2026 results on Nov 13, 2025
お知らせ • Aug 28Trident Texofab Limited, Annual General Meeting, Sep 25, 2025Trident Texofab Limited, Annual General Meeting, Sep 25, 2025, at 16:00 Indian Standard Time.
Reported Earnings • Aug 15First quarter 2026 earnings released: EPS: ₹0.72 (vs ₹0.69 in 1Q 2025)First quarter 2026 results: EPS: ₹0.72 (up from ₹0.69 in 1Q 2025). Revenue: ₹285.2m (up 11% from 1Q 2025). Net income: ₹10.2m (up 46% from 1Q 2025). Profit margin: 3.6% (up from 2.7% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Aug 07Trident Texofab Limited to Report Q1, 2026 Results on Aug 12, 2025Trident Texofab Limited announced that they will report Q1, 2026 results on Aug 12, 2025
Reported Earnings • May 30Full year 2025 earnings released: EPS: ₹2.38 (vs ₹1.07 in FY 2024)Full year 2025 results: EPS: ₹2.38 (up from ₹1.07 in FY 2024). Revenue: ₹1.25b (up 26% from FY 2024). Net income: ₹25.1m (up 132% from FY 2024). Profit margin: 2.0% (up from 1.1% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 23% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 21Trident Texofab Limited to Report Q4, 2025 Results on May 29, 2025Trident Texofab Limited announced that they will report Q4, 2025 results on May 29, 2025
New Risk • Apr 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 35% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.8x net interest cover). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₹2.34b market cap, or US$27.3m).
Reported Earnings • Feb 04Third quarter 2025 earnings released: EPS: ₹0.30 (vs ₹0.55 in 3Q 2024)Third quarter 2025 results: EPS: ₹0.30 (down from ₹0.55 in 3Q 2024). Revenue: ₹314.3m (up 37% from 3Q 2024). Net income: ₹3.00m (down 46% from 3Q 2024). Profit margin: 1.0% (down from 2.4% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jan 31Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹157, the stock trades at a trailing P/E ratio of 73.2x. Average trailing P/E is 32x in the Retail Distributors industry in India. Total returns to shareholders of 196% over the past three years.
お知らせ • Jan 29Trident Texofab Limited to Report Q3, 2025 Results on Feb 03, 2025Trident Texofab Limited announced that they will report Q3, 2025 results on Feb 03, 2025
Valuation Update With 7 Day Price Move • Oct 24Investor sentiment improves as stock rises 40%After last week's 40% share price gain to ₹105, the stock trades at a trailing P/E ratio of 49x. Average trailing P/E is 47x in the Retail Distributors industry in India. Total returns to shareholders of 141% over the past three years.
Recent Insider Transactions • Oct 18MD & Executive Chairman recently sold ₹54m worth of stockOn the 16th of October, Hardik Desai sold around 1m shares on-market at roughly ₹54.13 per share. This transaction amounted to 32% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Hardik has been a net seller over the last 12 months, reducing personal holdings by ₹59m.
Reported Earnings • Oct 14Second quarter 2025 earnings released: EPS: ₹1.00 (vs ₹0.75 in 2Q 2024)Second quarter 2025 results: EPS: ₹1.00 (up from ₹0.75 in 2Q 2024). Revenue: ₹292.1m (up 26% from 2Q 2024). Net income: ₹10.0m (up 33% from 2Q 2024). Profit margin: 3.4% (up from 3.2% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
お知らせ • Oct 08Trident Texofab Limited to Report Q2, 2025 Results on Oct 12, 2024Trident Texofab Limited announced that they will report Q2, 2025 results at 3:30 PM, Indian Standard Time on Oct 12, 2024
お知らせ • Aug 22Trident Texofab Limited, Annual General Meeting, Sep 27, 2024Trident Texofab Limited, Annual General Meeting, Sep 27, 2024, at 16:00 Indian Standard Time.
Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹44.56, the stock trades at a trailing P/E ratio of 23.6x. Average trailing P/E is 49x in the Retail Distributors industry in India. Total returns to shareholders of 23% over the past three years.
Reported Earnings • Jul 20First quarter 2025 earnings released: EPS: ₹0.69 (vs ₹0.13 loss in 1Q 2024)First quarter 2025 results: EPS: ₹0.69 (up from ₹0.13 loss in 1Q 2024). Revenue: ₹265.8m (up 15% from 1Q 2024). Net income: ₹6.96m (up ₹8.24m from 1Q 2024). Profit margin: 2.6% (up from net loss in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 13Trident Texofab Limited to Report Q1, 2025 Results on Jul 17, 2024Trident Texofab Limited announced that they will report Q1, 2025 results on Jul 17, 2024
Recent Insider Transactions • Jul 02MD & Executive Chairman recently sold ₹4.5m worth of stockOn the 27th of June, Hardik Desai sold around 94k shares on-market at roughly ₹48.33 per share. This transaction amounted to 2.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Hardik's only on-market trade for the last 12 months.
Valuation Update With 7 Day Price Move • Jul 01Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹40.16, the stock trades at a trailing P/E ratio of 37.5x. Average trailing P/E is 50x in the Retail Distributors industry in India. Total returns to shareholders of 4.9% over the past three years.
Reported Earnings • Feb 15Third quarter 2024 earnings released: EPS: ₹0.55 (vs ₹1.14 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.55 (down from ₹1.14 in 3Q 2023). Revenue: ₹231.2m (down 5.8% from 3Q 2023). Net income: ₹5.58m (down 52% from 3Q 2023). Profit margin: 2.4% (down from 4.7% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 07Trident Texofab Limited to Report Q3, 2024 Results on Feb 14, 2024Trident Texofab Limited announced that they will report Q3, 2024 results on Feb 14, 2024
お知らせ • Oct 28Trident Texofab Limited to Report Q2, 2024 Results on Nov 06, 2023Trident Texofab Limited announced that they will report Q2, 2024 results on Nov 06, 2023
お知らせ • Oct 12Trident Texofab Limited Announces Resignation of Deepak Prakashchandra Gandhi from the BoardTrident Texofab Limited informed that Mr. Deepak Prakashchandra Gandhi has vide his resignation letter dated October 11, 2023, resigned from the Board of the Company with effect from the closure of business hours on 11th October, 2023.
Valuation Update With 7 Day Price Move • Sep 11Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹73.75, the stock trades at a trailing P/E ratio of 40.1x. Average trailing P/E is 39x in the Retail Distributors industry in India. Total returns to shareholders of 157% over the past three years.
Reported Earnings • Aug 12First quarter 2024 earnings released: ₹0.13 loss per share (vs ₹0.23 profit in 1Q 2023)First quarter 2024 results: ₹0.13 loss per share (down from ₹0.23 profit in 1Q 2023). Revenue: ₹231.8m (flat on 1Q 2023). Net loss: ₹1.29m (down 154% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
お知らせ • Aug 11+ 1 more updateTrident Texofab Limited, Annual General Meeting, Sep 29, 2023Trident Texofab Limited, Annual General Meeting, Sep 29, 2023, at 17:00 Indian Standard Time.
お知らせ • Jul 29Trident Texofab Limited to Report Q1, 2024 Results on Aug 10, 2023Trident Texofab Limited announced that they will report Q1, 2024 results on Aug 10, 2023
お知らせ • Jul 16Trident Texofab Limited Announces Resignation of Vrusti Bhumik Patel as Independent DirectorTrident Texofab Limited announced that Mrs. Vrusti Bhumik Patel has vide her resignation letter dated 15 July 2023, resigned from the board of the company with effect from the closure of business hours on 15 July 2023.
Board Change • Jul 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 2 highly experienced directors. Executive & Non-Independent Director Manish Halwawala was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 04Trident Texofab Limited Announces Resignation of Rushi Hemantkumar Jagani as DirectorTrident Texofab Limited announced that Mr. Rushi Hemantkumar Jagani has vide his resignation letter dated June 2, 2023, resigned from the Board Of the Company with effect from the closure of business hours on 02nd June, 2023. Due to personal reasons and pre-occupation elsewhere and there is no other material reason for resignation.
Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹63.55, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 27x in the Retail Distributors industry in India. Total returns to shareholders of 47% over the past three years.
Valuation Update With 7 Day Price Move • Feb 07Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹66.05, the stock trades at a trailing P/E ratio of 23.5x. Average trailing P/E is 33x in the Retail Distributors industry in India. Total returns to shareholders of 80% over the past three years.
Reported Earnings • Jan 18Third quarter 2023 earnings released: EPS: ₹1.14 (vs ₹0.15 in 3Q 2022)Third quarter 2023 results: EPS: ₹1.14 (up from ₹0.15 in 3Q 2022). Revenue: ₹252.9m (up 6.0% from 3Q 2022). Net income: ₹11.5m (up ₹10.0m from 3Q 2022). Profit margin: 4.5% (up from 0.6% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 10Trident Texofab Limited to Report Q3, 2023 Results on Jan 16, 2023Trident Texofab Limited announced that they will report Q3, 2023 results at 3:30 PM, Indian Standard Time on Jan 16, 2023
お知らせ • Jan 03Trident Texofab Limited Appoints Rahul Jariwala as Company Secretary and Compliance OfficerTrident Texofab Limited has approved the appointment of Mr. Rahul Jariwala as a Company Secretary and Compliance officer of the company with effective from 02 January, 2023.
Valuation Update With 7 Day Price Move • Dec 07Investor sentiment improved over the past weekAfter last week's 25% share price gain to ₹102, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 43x in the Retail Distributors industry in India. Total returns to shareholders of 170% over the past three years.
お知らせ • Oct 12Trident Texofab Limited Approves Resignation of Sanju Patel as Company Secretary and Compliance OfficerTrident Texofab Limited at its meeting held on October 11, 2022, the Board of Directors approved resignation of Ms. Sanju Patel from the post of Company Secretary and Compliance Officer, effective closure of business hours on October 11, 2022 due to her personal reasons.
Reported Earnings • Oct 12Second quarter 2023 earnings released: EPS: ₹0.77 (vs ₹0.02 in 2Q 2022)Second quarter 2023 results: EPS: ₹0.77 (up from ₹0.02 in 2Q 2022). Net income: ₹7.77m (up ₹7.62m from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Oct 05Trident Texofab Limited to Report Q2, 2023 Results on Oct 11, 2022Trident Texofab Limited announced that they will report Q2, 2023 results on Oct 11, 2022
お知らせ • Aug 23Trident Texofab Limited, Annual General Meeting, Sep 26, 2022Trident Texofab Limited, Annual General Meeting, Sep 26, 2022, at 11:00 Indian Standard Time. Location: 5th Floor, Office Building Nr. Sahara Darwaja Surat India
Recent Insider Transactions • Aug 09MD & Executive Chairman recently sold ₹3.6m worth of stockOn the 4th of August, Hardik Desai sold around 32k shares on-market at roughly ₹114 per share. In the last 3 months, they made an even bigger sale worth ₹5.9m. Hardik has been a seller over the last 12 months, reducing personal holdings by ₹12m.
お知らせ • Jul 09Trident Texofab Limited Announces Resignation of Board MembersTrident Texofab Limited announced the resignation of Ms. Ami Ashwinbhai Desai and inducting Mrs. Natasha Karbhari, Independent Director as new Member of the Audit Committee, Nomination & Remuneration Committee and member of Relationship Committee, with immediate effect.
お知らせ • Jul 07Trident Texofab Limited to Report Q1, 2023 Results on Jul 12, 2022Trident Texofab Limited announced that they will report Q1, 2023 results at 3:30 PM, Indian Standard Time on Jul 12, 2022
お知らせ • Jul 02Trident Texofab Limited Announces Resignation of Ami Ashwinbhai Desai as Independent DirectorTrident Texofab Limited informed that Ms. Ami Ashwinbhai Desai has tendered her resignation due to her personal reasons and other professional commitments as an Independent Director from the Board of Directors of the Company vide her letter dated July 1, 2022 effective the closure of business hours on 09th July, 2022.
Recent Insider Transactions • Jun 07MD & Executive Chairman recently sold ₹707k worth of stockOn the 3rd of June, Hardik Desai sold around 7k shares on-market at roughly ₹101 per share. In the last 3 months, they made an even bigger sale worth ₹5.9m. Hardik has been a seller over the last 12 months, reducing personal holdings by ₹8.2m.
Recent Insider Transactions • May 28MD & Executive Chairman recently sold ₹5.9m worth of stockOn the 25th of May, Hardik Desai sold around 60k shares on-market at roughly ₹98.89 per share. This was the largest sale by an insider in the last 3 months. Hardik has been a seller over the last 12 months, reducing personal holdings by ₹7.5m.
Recent Insider Transactions • Apr 30MD & Executive Chairman recently sold ₹5.6m worth of stockOn the 27th of April, Hardik Desai sold around 55k shares on-market at roughly ₹103 per share. This was the largest sale by an insider in the last 3 months. This was Hardik's only on-market trade for the last 12 months.
Reported Earnings • Apr 27Full year 2022 earnings released: EPS: ₹0.98 (vs ₹0.35 in FY 2021)Full year 2022 results: EPS: ₹0.98 (up from ₹0.35 in FY 2021). Revenue: ₹850.3m (up 70% from FY 2021). Net income: ₹9.83m (up 178% from FY 2021). Profit margin: 1.2% (up from 0.7% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 34% per year, which means it is well ahead of earnings.
お知らせ • Apr 16Trident Texofab Limited to Report Q4, 2022 Results on Apr 21, 2022Trident Texofab Limited announced that they will report Q4, 2022 results on Apr 21, 2022
Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹63.35, the stock trades at a trailing P/E ratio of 72.5x. Average trailing P/E is 49x in the Retail Distributors industry in India. Total returns to shareholders of 58% over the past three years.
Reported Earnings • Oct 22Second quarter 2022 earnings released: EPS ₹0.02 (vs ₹0.14 in 2Q 2021)The company reported a mediocre second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹212.9m (up 36% from 2Q 2021). Net income: ₹157.0k (down 89% from 2Q 2021). Profit margin: 0.1% (down from 0.9% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improved over the past weekAfter last week's 28% share price gain to ₹50.55, the stock trades at a trailing P/E ratio of 48.6x. Average trailing P/E is 53x in the Retail Distributors industry in India. Total returns to shareholders of 23% over the past three years.
Valuation Update With 7 Day Price Move • Sep 14Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹40.00, the stock trades at a trailing P/E ratio of 38.7x. Average trailing P/E is 52x in the Retail Distributors industry in India. Total loss to shareholders of 5.3% over the past three years.
Reported Earnings • Jul 02Full year 2021 earnings released: EPS ₹0.35 (vs ₹0.90 in FY 2020)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹499.3m (down 45% from FY 2020). Net income: ₹3.53m (down 59% from FY 2020). Profit margin: 0.7% (down from 0.9% in FY 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
Executive Departure • Apr 21Non-Executive Non-Independent Director has left the companyOn the 15th of April, Maniya Desai's tenure as Non-Executive Non-Independent Director ended after 3.9 years in the role. As of December 2020, Maniya personally held only 98.20k shares (₹3.0m worth at the time). A total of 2 executives have left over the last 12 months.
Executive Departure • Apr 02Company Secretary & Compliance Officer has left the companyOn the 31st of March, Mehul Amareliya's tenure as Company Secretary & Compliance Officer ended after 3.1 years in the role. We don't have any record of a personal shareholding under Mehul's name. Mehul is the only executive to leave the company over the last 12 months.
Reported Earnings • Feb 12Third quarter 2021 earnings released: EPS ₹0.08 (vs ₹0.24 in 3Q 2020)The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹140.0m (down 30% from 3Q 2020). Net income: ₹790.0k (down 66% from 3Q 2020). Profit margin: 0.6% (down from 1.2% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 05Trident Texofab Limited to Report Q3, 2021 Results on Feb 11, 2021Trident Texofab Limited announced that they will report Q3, 2021 results on Feb 11, 2021
Is New 90 Day High Low • Feb 02New 90-day low: ₹24.25The company is down 7.0% from its price of ₹26.00 on 04 November 2020. The Indian market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is up 30% over the same period.
Is New 90 Day High Low • Dec 12New 90-day high: ₹33.10The company is up 20% from its price of ₹27.50 on 11 September 2020. The Indian market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Retail Distributors industry, which is up 14% over the same period.
Is New 90 Day High Low • Nov 25New 90-day high: ₹30.00The company is up 2.0% from its price of ₹29.30 on 27 August 2020. The Indian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is up 7.0% over the same period.
Reported Earnings • Nov 13Second quarter 2021 earnings released: EPS ₹0.14The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: ₹158.2m (down 29% from 2Q 2020). Net income: ₹1.45m (up 5.5% from 2Q 2020). Profit margin: 0.9% (up from 0.6% in 2Q 2020). The increase in margin was driven by lower expenses.
お知らせ • Nov 06Trident Texofab Limited to Report Q2, 2021 Results on Nov 11, 2020Trident Texofab Limited announced that they will report Q2, 2021 results on Nov 11, 2020
Is New 90 Day High Low • Oct 26New 90-day low: ₹26.15The company is down 14% from its price of ₹30.31 on 27 July 2020. The Indian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is up 8.0% over the same period.
Is New 90 Day High Low • Oct 08New 90-day low: ₹26.40The company is down 11% from its price of ₹29.58 on 10 July 2020. The Indian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Retail Distributors industry, which is up 13% over the same period.
お知らせ • Aug 18Trident Texofab Limited to Report Q1, 2021 Results on Aug 20, 2020Trident Texofab Limited announced that they will report Q1, 2021 results on Aug 20, 2020
お知らせ • Jun 20Trident Texofab Limited to Report Q4, 2020 Results on Jun 25, 2020Trident Texofab Limited announced that they will report Q4, 2020 results on Jun 25, 2020